Opportunity Information: Apply for PA 13 377
Apply for PA 13 377
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Research on Malignancies in the Context of HIV/AIDS (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.393 Cancer Cause and Prevention Research.
- This funding opportunity was created on Oct 21, 2013 and posted on Oct 21, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education County governments Small businesses State governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Public housing authorities/Indian housing authorities Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Research on Malignancies in the Context of HIV/AIDS (R01) is an NIH funding opportunity (PA 13-377) that supported investigator-initiated Research Project Grant (R01) applications focused on cancers that occur in people living with HIV or with AIDS. The central aim of the program was to keep pushing the science forward on how, why, and when these malignancies arise, how they progress, how they can be diagnosed earlier or more accurately, and how they can be treated more effectively in the setting of HIV-related immune dysfunction. The announcement reflects a clear interest in work that connects mechanistic understanding with real clinical impact, especially research that can ultimately improve screening strategies and tailor therapies for HIV-infected populations.
From a scientific scope standpoint, the FOA emphasized both AIDS-defining malignancies and non-AIDS-defining malignancies, and it encouraged studies across diverse populations. That includes projects examining etiologic factors and cofactors (for example, behavioral, environmental, genetic, and infectious contributors), immunopathogenesis (how immune changes driven by HIV shape cancer initiation and progression), diagnostic approaches, and the short- and long-term consequences of these cancers for individuals living with HIV. A major theme was teasing apart what is specifically attributable to HIV infection itself versus what results from interactions between HIV and other pathogens that are common in this population and known to contribute to cancer risk. In practice, this could encompass studies looking at the role of immune suppression, chronic inflammation, viral co-infections, and treatment-related factors in driving cancer incidence, aggressiveness, response to therapy, and survivorship outcomes.
The FOA also highlighted two especially important outcomes the NIH wanted applicants to address. First, it encouraged research that generates solid evidence on clinical outcomes of cancers in HIV-infected people, which can include prognosis, treatment tolerance, recurrence patterns, complications, and survival compared with HIV-negative populations. Second, it sought research that identifies the specific contributions of HIV and HIV-related biology, including potential synergy with other pathogens, in the development and pathogenesis of these cancers. The intended payoff of this work was practical: better risk stratification, improved screening and prevention approaches, and therapies designed or optimized for the unique clinical and biological context of HIV infection.
Administratively, this opportunity fell under the NIH discretionary grant category and used the R01 mechanism, meaning it was designed for substantial, multi-year research projects that can support a defined, hypothesis-driven plan. It was associated with NIH institutes including the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR), and it aligned with CFDA program areas 93.393 (Cancer Cause and Prevention Research) and 93.121 (Oral Diseases and Disorders Research), signaling that relevant projects could range from broad oncology questions to cancers and malignant conditions affecting oral and craniofacial health in the context of HIV.
Eligibility was broad and included many types of domestic and non-domestic organizations. Eligible applicants listed in the announcement included public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations (including small businesses), independent school districts, and a wide range of government entities (city, county, state, tribal, special district, and public housing authorities/Indian housing authorities). The FOA also explicitly included many categories of institutions and organizations that NIH often highlights for inclusion, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based and community-based organizations where appropriate. Importantly, foreign organizations and foreign institutions were eligible to apply, non-U.S. components of U.S. organizations were eligible, and foreign components (as defined by NIH policy) were allowed, which supported international or multinational research efforts when scientifically justified. The opportunity did not require cost sharing or matching.
In terms of timing, the FOA was posted and created on October 21, 2013, and it originally closed on September 7, 2016, with the archive date listed as October 8, 2016. The sponsor agency was the National Institutes of Health, and the full announcement was made available through the NIH grants guide at the provided link. For technical access issues, the contact point listed was the NIH Office of Extramural Research (OER) webmaster.
Frequently Asked Questions (FAQs)
1) What is the "Research on Malignancies in the Context of HIV/AIDS (R01)" funding opportunity?
It is an NIH funding opportunity announcement (FOA) identified as PA 13-377 that supported investigator-initiated Research Project Grant (R01) applications focused on cancers that occur in people living with HIV or with AIDS.
2) What is the main goal of this FOA?
The central aim was to advance research on how, why, and when HIV-associated malignancies arise, how they progress, how they can be diagnosed earlier or more accurately, and how they can be treated more effectively in the setting of HIV-related immune dysfunction. The FOA also reflects interest in linking mechanistic understanding to meaningful clinical impact, including improved screening strategies and better-tailored therapies for HIV-infected populations.
3) What grant mechanism does this opportunity use?
This opportunity used the NIH R01 mechanism (Research Project Grant), intended for substantial, multi-year research projects supporting a defined, hypothesis-driven research plan.
4) What types of cancers were within the scientific scope?
The FOA emphasized both AIDS-defining malignancies and non-AIDS-defining malignancies occurring in people living with HIV or AIDS.
5) What kinds of research topics were encouraged?
The FOA encouraged studies addressing etiologic factors and cofactors (including behavioral, environmental, genetic, and infectious contributors), immunopathogenesis (how HIV-driven immune changes shape cancer initiation and progression), diagnostic approaches, and the short- and long-term consequences of these cancers for individuals living with HIV.
6) Did the FOA encourage research across diverse populations?
Yes. The FOA encouraged studies across diverse populations.
7) What does "etiologic factors and cofactors" mean in the context of this FOA?
Within this FOA, etiologic factors and cofactors include potential contributors to cancer risk and development in people with HIV, such as behavioral factors, environmental exposures, genetic influences, and infectious contributors.
8) What does "immunopathogenesis" refer to here?
In this FOA, immunopathogenesis refers to how immune changes driven by HIV influence cancer initiation and progression, including the roles of immune suppression and chronic inflammation.
9) Was there a focus on interactions between HIV and other pathogens?
Yes. A major theme was distinguishing what is specifically attributable to HIV infection itself versus what results from interactions between HIV and other pathogens common in this population that are known to contribute to cancer risk. The FOA also noted potential synergy with other pathogens in cancer development and pathogenesis.
10) What kinds of biological or clinical drivers were considered relevant?
Examples described include immune suppression, chronic inflammation, viral co-infections, and treatment-related factors, as they may influence cancer incidence, aggressiveness, response to therapy, and survivorship outcomes in people living with HIV.
11) What were the two especially important outcomes NIH wanted applicants to address?
First, research generating solid evidence on clinical outcomes of cancers in HIV-infected people (including prognosis, treatment tolerance, recurrence patterns, complications, and survival compared with HIV-negative populations). Second, research identifying the specific contributions of HIV and HIV-related biology, including potential synergy with other pathogens, in the development and pathogenesis of these cancers.
12) What kinds of clinical outcomes were explicitly mentioned?
The FOA referenced prognosis, treatment tolerance, recurrence patterns, complications, and survival, including comparisons with HIV-negative populations.
13) What practical benefits did NIH expect from research supported by this FOA?
The intended payoff included better risk stratification, improved screening and prevention approaches, and therapies designed or optimized for the unique clinical and biological context of HIV infection.
14) Which NIH institutes were associated with this opportunity?
The FOA was associated with NIH institutes including the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR).
15) What CFDA program areas were referenced?
The FOA aligned with CFDA program areas 93.393 (Cancer Cause and Prevention Research) and 93.121 (Oral Diseases and Disorders Research).
16) Does this FOA include oral or craniofacial cancers and related malignant conditions in the context of HIV?
Yes. The referenced CFDA areas and the involvement of NIDCR indicate that relevant projects could include cancers and malignant conditions affecting oral and craniofacial health in the context of HIV, in addition to broader oncology questions.
17) Who was eligible to apply?
Eligibility was broad and included many types of domestic and non-domestic organizations. Eligible applicants included public and private institutions of higher education, nonprofit organizations (with and without 501(c)(3) status), for-profit organizations (including small businesses), independent school districts, and many government entities (including city, county, state, tribal, special district, and public housing authorities/Indian housing authorities).
18) Were minority-serving institutions and community/faith-based organizations included in eligibility?
Yes. The FOA explicitly included categories often highlighted for inclusion, such as HBCUs, Hispanic-serving institutions, TCCUs, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs, along with faith-based and community-based organizations where appropriate.
19) Were foreign (non-U.S.) organizations allowed to apply?
Yes. Foreign organizations and foreign institutions were eligible to apply. In addition, non-U.S. components of U.S. organizations were eligible, and foreign components (as defined by NIH policy) were allowed, supporting international or multinational research efforts when scientifically justified.
20) Was cost sharing or matching required?
No. The opportunity did not require cost sharing or matching.
21) What was the funding category for this opportunity?
Administratively, this opportunity fell under the NIH discretionary grant category.
22) When was the FOA posted, and when did it close?
The FOA was posted and created on October 21, 2013. It originally closed on September 7, 2016, and the archive date listed was October 8, 2016.
23) Who was the sponsor agency?
The sponsor agency was the National Institutes of Health (NIH).
24) Where was the full announcement made available?
The full announcement was made available through the NIH grants guide at the link provided in the opportunity materials.
25) Who was listed as the contact for technical access issues?
For technical access issues, the contact point listed was the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Collaborative Research
Previous opportunity: Research on Malignancies in the Context of HIV/AIDS (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 377
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 377) also looked into and applied for these:
| Funding Opportunity |
|---|
| Sub Saharan African Collaborative HIV and Cancer Consortia (U54) Apply for RFA CA 13 010 Funding Number: RFA CA 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| FY 2014 American Schools and Hospitals Abroad (ASHA) Program Apply for APS ASHA 14 000001 Funding Number: APS ASHA 14 000001 Agency: Agency for International Development Category: Education Health Funding Amount: $2,000,000 |
| Cancer Detection, Diagnostic and Treatment Technologies for Global Health (UH2/UH3) Apply for RFA CA 13 015 Funding Number: RFA CA 13 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Population based Research Optimizing Screening through Personalized Regimens (PROSPR) Revision to Enhance the Collection of Cervical Cancer Screening Data (U54) Apply for RFA CA 14 001 Funding Number: RFA CA 14 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $650,000 |
| Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30) Apply for PAR 13 386 Funding Number: PAR 13 386 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Low Cost, Pragmatic, Patient Centered Randomized Controlled Intervention Trials (UH2/UH3) Apply for RFA HL 14 019 Funding Number: RFA HL 14 019 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R41/R42) Apply for PA 13 388 Funding Number: PA 13 388 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R43/R44) Apply for PA 13 387 Funding Number: PA 13 387 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program(NCORP) Community Sites (UM1) Apply for RFA CA 13 013 Funding Number: RFA CA 13 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Research Bases (UM1) Apply for RFA CA 13 012 Funding Number: RFA CA 13 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites (UM1) Apply for RFA CA 13 014 Funding Number: RFA CA 13 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exceptional Unconventional Research Enabling Knowledge Acceleration (EUREKA) for Neuroscience and Disorders of the Nervous System (R01) Apply for RFA MH 14 214 Funding Number: RFA MH 14 214 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Indo US Collaborative Program on Affordable Medical Devices (R03) Apply for PAR 13 390 Funding Number: PAR 13 390 Agency: National Institutes of Health Category: Education Health Funding Amount: $75,000 |
| NCI Small Grants Program for Cancer Research (NCI Omnibus R03) Apply for PAR 14 007 Funding Number: PAR 14 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Identification of Gene Variants for Addiction Related Traits by Next Gen Sequencing in Model Organisms Selectively Bred for Addiction Traits (UH2/UH3) Apply for PAR 14 010 Funding Number: PAR 14 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| The Palliative Care Research Cooperative (PCRC) Enhancing Sustainability and Building the Science of Palliative Care (R01) Apply for RFA NR 14 003 Funding Number: RFA NR 14 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Revision Applications for Research on Genomic Underpinnings of Response to Rehabilitation Interventions (R01) Apply for PAR 14 012 Funding Number: PAR 14 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Genomic Underpinnings of Response to Rehabilitation Interventions (R01) Apply for PAR 14 011 Funding Number: PAR 14 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Functional Genetics, Epigenetics, and Non coding RNAs in Substance Abuse (R01) Apply for PA 14 014 Funding Number: PA 14 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Functional Genetics, Epigenetics, and Non coding RNAs in Substance Abuse (R21) Apply for PA 14 013 Funding Number: PA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 377", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.